On April 24, 2024, Femasys Inc., a medical technology company, disclosed a regulatory filing with the SEC, indicating the release of an updated corporate presentation. The presentation, now available on the company's website, is attached as Exhibit 99.1 to the Form 8-K report. Femasys, which is listed on The Nasdaq Stock Market under the ticker FEMY, will utilize the presentation in forthcoming discussions with investors, analysts, and other interested parties. The company, identified as an emerging growth company, has also chosen not to use the extended transition period for complying with new or revised financial accounting standards. The information provided in the presentation is for informational purposes and is not considered filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into any filings under the Securities Act of 1933, unless explicitly stated in such filings. Femasys's CEO, Kathy Lee-Sepsick, has signed off on the report, affirming the company's compliance with SEC requirements.

On April 24, 2024, Femasys Inc., a medical technology company, disclosed a regulatory filing with the SEC, indicating the release of an updated corporate presentation. The presentation, now available on the company's website, is attached as Exhibit 99.1 to the Form 8-K report. Femasys, which is listed on The Nasdaq Stock Market under the ticker FEMY, will utilize the presentation in forthcoming discussions with investors, analysts, and other interested parties. The company, identified as an emerging growth company, has also chosen not to use the extended transition period for complying with new or revised financial accounting standards. The information provided in the presentation is for informational purposes and is not considered filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into any filings under the Securities Act of 1933, unless explicitly stated in such filings. Femasys's CEO, Kathy Lee-Sepsick, has signed off on the report, affirming the company's compliance with SEC requirements.